A promising new antibiotic, gepotidacin, emerged as a potential weapon against drug-resistant gonorrhea, according to a recent study published in The Lancet. The clinical trial, involving 628 ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

A new pill has shown promise against antibiotic-resistant gonorrhoea — a common sexually transmitted infection (STI) — ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea. In the EAGLE-1 ...

Another emerging therapy showing promise in addressing patients with recurrent UTIs is gepotidacin, based on the EAGLE-2 and EAGLE-3trial findings. How is gepotidacin’s mechanism of action ...

Gonorrhea is a sexually transmitted disease caused by Neisseria gonorrhoeae bacteria A new oral antibiotic, gepotidacin, may treat gonorrhea The drug showed similar success rates to current ...

Panelists discuss how newer urinary tract infection (UTI) therapies such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin demonstrate significantly lower resistance rates (below ...

Penmenvy, GSK’s pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating, uncomplicated urinary tract infection were approved in the United States in the first quarter of ...

New approvals in the quarter included the meningitis vaccine Penmenvy and the first-in-class antibiotic Blujepa (gepotidacin). However, vaccine revenues declined 6% to £2.1bn, reflecting softer demand ...